At a glance
ClinicalIndex Comparison RecordN/ACompleted· 11 enrolled
Drug / intervention
Juvederm® VOLITEdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Open-Label Study, to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite Injection on Healthy Volunteers
In Brief
A clinical study evaluating Juvederm® VOLITE for Healthy Adults and Skin Enhancement. Completed, enrolled 11 participants across 1 site.
Detailed Summary
To evaluate the impact on skin quality attributes, including physical measurements and gene and protein expression (histological and genomic analysis), following administration of Juvéderm® VOLITE in the volar forearms of healthy volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Adults, Skin Enhancement
CountriesPoland
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartOct 2019
First PostedDec 2019
Primary CompletionJul 2020
TodayJul 2026
First PostedDec 20, 2019
Enrollment StartOct 8, 2019
Primary CompletionJul 29, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.5 years ago
Interventions
Juvederm® VOLITEdevice
1 mL of Juvéderm® VOLITE contains hyaluronic acid gel 12.0 milligram (mg), lidocaine hydrochloride 3.0 mg in a phosphate buffer pH 7.2 q.s. 1 mL (or gram).